Overview

TOL-463 Phase 2 Study for Vaginitis

Status:
Completed
Trial end date:
2017-06-10
Target enrollment:
Participant gender:
Summary
This is a Phase II study designed to assess the safety and efficacy of an investigational product, TOL-463, to treat vaginitis.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Toltec Pharmaceuticals, LLC
Treatments:
TOL-463